Fatima Zahra Bellefkih, Radiation Oncologist, shared on LinkedIn:
“I am delighted to share the publication of our article in JCO Global Oncology.
This collaborative work, developed through AROME and OMM, provides practical expert recommendations on the safe integration of radiotherapy with emerging systemic therapies for breast cancer, including antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and CDK4/6 inhibitors.
Key takeaways:
- Practical guidance for combining radiotherapy with novel systemic therapies in routine clinical practice.
- Evidence-based recommendations complemented by expert consensus where prospective data remain limited.
- A particular focus on the challenges and opportunities in low- and middle-income countries.
- Emphasis on multidisciplinary decision-making and individualized patient care to optimize both efficacy and safety.
I would like to express my sincere gratitude to Prof. Belkacemi for his leadership, vision, and for initiating this important project. My heartfelt thanks also go to Kamel Debbi for his outstanding work in drafting the manuscript and his dedication throughout the project. Finally, I am grateful to all co-authors and collaborators for their valuable contributions.
It is an honor to have contributed to this work, and I hope it will support clinicians worldwide in optimizing breast cancer care.”
Title: Concurrent New Systemic Therapies and Radiation Therapy in Breast Cancer: Current Evidence, Future Challenges, and Expert Practice Recommendations for Low- and Middle-Income Countries
Authors: Kamel Debbi, Fatima Zahra Bellefkih, Alexander Bennassi, Meriem El Bachiri, Salma El Mouhtadi, Youssef Bensouda, Lahcene Belaidi, Kawtar El Hassani, Sami Frikha, Nisrine El Hayel, Dusanka Tešanović, Pelagia G.Tsoutsou, Joseph Gligorov, Yazid Belkacemi.
Read the full article.
This also can be interesting:
SUPREMO: Chest Wall Radiotherapy Has Limited 5-Year QOL Impact
